Analysis

A Strong Quarter, but Teva’s Not Yet Out of the Woods

Teva remains reliant on a small number of branded drugs that will face generic competition soon and is having trouble getting its pipeline of new treatments into the market

Yoram Gabison
Yoram Gabison
Send in e-mailSend in e-mail
Israeli flag flies outside Teva Pharmaceutical facility building in Neot Hovav, Israel, in December 2017
Israeli flag flies outside Teva Pharmaceutical facility building in Neot Hovav, Israel, in December 2017Credit: Tsafrir Abayov/AP

Comments